COL18A1 and idiopathic pulmonary fibrosis: Celecoxib is the only candidate targeting all 3 “green” pathways of IPF. Specifically, celecoxib is an anti-inflammatory drug that we identify in the CoDReS results for IPF. Celecoxib targets the CA2 and COL18A1 genes in “Pancreatic secretion” and “Protein digestion and absorption” pathways respectively and PLAU in “Complement and coagulation cascades”.